Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Failure of Ceftriaxone in the Treatment of Acute Brucellosis

Ruth Lang, Ron Dagan, Israel Potasman, Menahem Einhorn and Raul Raz
Clinical Infectious Diseases
Vol. 14, No. 2 (Feb., 1992), pp. 506-509
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4456319
Page Count: 4
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Failure of Ceftriaxone in the Treatment of Acute Brucellosis
Preview not available

Abstract

In an open, multicenter study conducted in Israel in 1989, 18 patients with acute brucellosis were randomized to receive either ≤2 g of intramuscularly administered ceftriaxone daily for at least 2 weeks or doxycycline for 4 weeks plus streptomycin for 2 weeks. All 10 patients treated with the combination of doxycycline plus streptomycin responded promptly, and their infections did not relapse during 6 months of follow-up. Of eight patients treated with ceftriaxone, six did not respond initially; when ceftriaxone was replaced by the combination of doxycycline and streptomycin, patients responded immediately. No relapses of infection were observed in these patients during follow-up. One patient who received ceftriaxone responded and remained well at the end of 6 months of follow-up, and one patient who initially responded to therapy with this drug experienced relapse of infection within 3 weeks but recovered when the doxycycline/streptomycin regimen was initiated. We conclude that despite encouraging data from in vitro studies and promising clinical studies, 2 g of ceftriaxone administered im daily should not be considered appropriate therapy for brucellosis.

Page Thumbnails

  • Thumbnail: Page 
506
    506
  • Thumbnail: Page 
507
    507
  • Thumbnail: Page 
508
    508
  • Thumbnail: Page 
509
    509